Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Key model inputs

From: Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China

Trial registration identifier

Group

Endpoint

Survival model

Parameter

Scale

Shape

NCT01761266

Lenvatinib

PFS

Log-logistic

7.00

1.68

OS

Log-logistic

13.62

1.77

Sorafenib

PFS

Log-logistic

4.21

1.56

OS

Log-logistic

12.52

1.59

NCT03434379

Atezolizumab-Bevacizumab

PFS

Weibull

0.08

1.09

OS

Log-logistic

21.03

1.32

NCT03794440

Sintilimab-Bevacizumab

PFS

Log-logistic

4.85

1.35

OS

Log-logistic

15.88

1.71

  1. OS overall survival, PFS progression-free survival
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us